Clinical trial Recruiting at 1 site Observational Ages 18 and up

β2M Levels After Hemodialysis: Predicting Post-Dialysis Rebound

Official title: Predicting the Post-dialysis Rebound of β2-microglobulin

Run by East and North Hertfordshire NHS Trust · NCT07713680 · Data updated 2026-11-12

This study tests whether measuring blood levels of β2-microglobulin in people on long-term hemodialysis can help predict how much the protein reappears in the blood after dialysis.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment30 (estimated)
SponsorEast and North Hertfordshire NHS Trust
Government
Locations1 site (Stevenage)
StatusRecruiting
StartedFebruary 24, 2026
Main results expectedNovember 2026
Study endsNovember 2026
Registry record updatedOctober 16, 2026
Trial IDNCT07713680 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 and older with end-stage renal disease on maintenance hemodialysis for at least 3 months who can provide informed consent.

Probably not a fit

Patients unable to consent or those with an acute infection within the past two weeks may not benefit from this observational assessment.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study follows adults with end-stage renal disease who are on maintenance hemodialysis to observe β2-microglobulin blood concentrations. Researchers will measure levels before and after dialysis to understand how much rebound occurs between sessions. The goal is to see if post-dialysis rebound can be predicted based on initial concentrations and dialysis-related factors. No intervention is being tested; the study aims to characterize natural fluctuations to inform patient management. The investigation is conducted at East and North Hertfordshire NHS Trust in Stevenage, with data collection under standard care conditions.

Why it matters

Potential benefit: If successful, the findings could help clinicians anticipate β2-microglobulin rebound and tailor monitoring or care for dialysis patients.

How similar studies have gone: Previous research has documented β2-microglobulin dynamics in dialysis, supporting the relevance of studying post-dialysis rebound.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 18 years or above.
* Ability to give informed consent.
* End Stage Renal Disease established on maintenance haemodialysis for at least 3 months

Exclusion Criteria:

* Inability to give informed consent.
* Acute infection in last 2 weeks.

Where it's running

  • East and North Hertfordshire NHS Trust
    Stevenage, United Kingdom
    Recruiting

Study contacts

  • Principal investigator: Shaza Adam — Lister Hospital, East and North Hertfordshire Teaching NHS Trust
  • Study coordinator: Shaza Adam, Clinical research Fellow
  • Email: Shaza.adam@nhs.net
  • Phone: 00447365073834

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.